Earnings ·
UroGen reports $89M Q3 revenue, ZUSDURI sales of $68M and FDA accepts NDA for UGN-103
URGNUroGen Pharma Ltd.
UroGen Pharma reported third-quarter 2026 total revenue of $89.0 million, driven by $68.0 million in net product revenue from ZUSDURI, representing 35% quarter-over-quarter growth. JELMYTO generated $21.0 million in revenue. The company posted a net loss of $1.5 million, or $0.03 per share, compared to a $33.3 million loss in the prior-year period. Additionally, UroGen announced that the FDA accepted its New Drug Application for UGN-103, with a PDUFA goal date set for June 14, 2027, and reported the first patient dosed in the Phase 1 trial for UGN-501. The company operates as a biotechnology firm developing and commercializing innovative treatments for urothelial and specialty cancers.